Trinity biotech announces q1 2024 financial results and reiterates guidance

-business performance on track to achieve approximately $20 million of annualized run-rate ebitdaso 1 on annualized revenues of approximately $75 million by q2 2025-

TRIB Ratings Summary

TRIB Quant Ranking